Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer.
Bottom Line: All cases were oestrogen receptor +, node negative, primary breast tumours from patients who later had no disease progression (tamoxifen sensitive) or whose disease progressed while on tamoxifen (tamoxifen resistant).Using an antibody to oestrogen receptor-beta that detects multiple forms of this protein (total) but not an antibody that detects only full-length oestrogen receptor-beta 1, it was found that high total oestrogen receptor beta protein expressors were more frequently observed in tamoxifen sensitive tumours than resistant tumours (Fisher's exact test, P=0.046).Altogether, there is little evidence for altered coregulators expression in breast tumours that are de novo tamoxifen resistant.
Affiliation: Manitoba Institute of Cell Biology, University of Manitoba, Faculty of Medicine, Winnipeg, Manitoba, Canada, R3E OW3. email@example.comShow MeSH
Related in: MedlinePlus
Mentions: IgYERbeta503 is an antibody that recognises ligand binding and non-ligand binding ORβ protein isoforms (Horvath et al, 2001; Saji et al, 2000) and which we refer to as total ORβ protein. Normal breast tissue was used as a positive control and is shown in Figure 2AFigure 2
Affiliation: Manitoba Institute of Cell Biology, University of Manitoba, Faculty of Medicine, Winnipeg, Manitoba, Canada, R3E OW3. firstname.lastname@example.org